Drugs / Lactobacillus salivarius WB21
Lactobacillus salivarius WB21
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03996044 | Jan → Jun 2021 | — | University of Nove de Julho | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus salivarius WB21 | “Group 3: probiotic capsule containing Lactobacillus salivarius WB21 (6.7 x 108 CFU) and xylitol (280mg), 3 times a day after meals, for 14 days;” PMID 38954692 ↗ Jul 2024 |
| Modality | Other / unclassified | “Biological: Probiotics” NCT03996044 ↗ |